Primary Hyperparathyroidism: Pathophysiology and Impact on Bone

Overview

Journal CMAJ

Date 2000 Aug 10

PMID 10934983

Citations 36

Authors

A Khan

J Bilezikian

Affiliations

Soon will be listed here.

Abstract

Primary hyperparathyroidism has been associated with bone loss, especially at cortical skeletal sites. Results from studies evaluating the mineral density of cancellous bone have been more difficult to interpret. Most densitometry studies support the concept that the parathyroid hormone appears to be catabolic at cortical sites and may have anabolic effects at cancellous bone sites. Studies completed to date, however, have been limited by design, definitions of fracture and inadequate control groups. Primary hyperparathyroidism is now increasingly being detected during the asymptomatic phase. The need for parathyroidectomy has been questioned in such patients because there may be no disease progression in the absence of surgery. Medical management of primary hyperparathyroidism has to date been limited to estrogen replacement therapy in postmenopausal women. Identification of the calcium receptor has improved our understanding of calcium homeostasis, and significant reductions in calcium receptor levels have been detected in parathyroid adenomas. Thus, a new class of therapeutics may include the calcimimetic agents. Bisphosphonates are also currently being evaluated with regard to their impact on fracture prevention and their beneficial effects on bone mineral density.

Citing Articles

Severe Headache and Deterioration of Vision in Left Eye in a Chronic Hemodialysis Patient Revealing a Brown Tumor of Sphenoid Sinus.

Esselmani H, Aimrane A, Chatoui H, El Hiba O, Najimi M, Merzouki M Neurol Int. 2025; 17(2).

PMID: 39997653 PMC: 11857977. DOI: 10.3390/neurolint17020022.

Persistent changes in calcium-regulating hormones and bone turnover markers in living kidney donors more than 20 years after donation.

Grossardt B, Kremers H, Miller A, Kasiske B, Matas A, Khosla S JBMR Plus. 2024; 8(7):ziae067.

PMID: 38868597 PMC: 11166890. DOI: 10.1093/jbmrpl/ziae067.

Outcomes of Surgical Management for Parathyroid Adenomas.

Dhingani G, Malik A, Singh V, Chaturvedi H, Nayyar R Indian J Otolaryngol Head Neck Surg. 2023; 75(4):3439-3442.

PMID: 37974675 PMC: 10646017. DOI: 10.1007/s12070-023-04006-7.

Primary Hyperparathyroidism in Older Adults: A Narrative Review of the Most Recent Literature on Epidemiology, Diagnosis and Management.

Rizk Y, Saad N, Arnaout W, Chalah M, Farah S J Clin Med. 2023; 12(19).

PMID: 37834965 PMC: 10573864. DOI: 10.3390/jcm12196321.

Pediatric hyperparathyroidism and ossification of the ligamentum flavum: A case report.

Thokalath A, Hayes L, Kucera J Radiol Case Rep. 2023; 18(9):3361-3365.

PMID: 37520389 PMC: 10375370. DOI: 10.1016/j.radcr.2023.07.009.

References

Reasner C, Stone M, Hosking D, Ballah A, Mundy G . Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab. 1993; 77(4):1067-71. DOI: 10.1210/jcem.77.4.8408454. View

Grey A, Stapleton J, Evans M, Reid I . Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism. Clin Endocrinol (Oxf). 1996; 44(6):697-702. DOI: 10.1046/j.1365-2265.1996.744565.x. View

Silverberg S, Bone 3rd H, Marriott T, Locker F, Dziem G, Kaatz S . Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med. 1997; 337(21):1506-10. DOI: 10.1056/NEJM199711203372104. View

Guo C, THOMAS W, Assiri A, Eastell R . Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 1996; 81(10):3487-91. DOI: 10.1210/jcem.81.10.8855790. View

Mulligan L, Kwok J, Healey C, Elsdon M, Eng C, Gardner E . Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993; 363(6428):458-60. DOI: 10.1038/363458a0. View

Silverberg S, Shane E, JACOBS T, Siris E, Bilezikian J . A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999; 341(17):1249-55. DOI: 10.1056/NEJM199910213411701. View

Dauphine R, Riggs B, SCHOLZ D . Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med. 1975; 83(3):365-7. DOI: 10.7326/0003-4819-83-3-365. View

Grey A, Mitnick M, Shapses S, Ellison A, Gundberg C, Insogna K . Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. J Clin Endocrinol Metab. 1996; 81(10):3450-4. DOI: 10.1210/jcem.81.10.8855783. View

Grey A, Cundy T, Reid I . Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol (Oxf). 1994; 40(5):671-7. DOI: 10.1111/j.1365-2265.1994.tb03020.x. View

10.

Wermers R, Khosla S, Atkinson E, Hodgson S, OFallon W, Melton 3rd L . The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med. 1997; 126(6):433-40. DOI: 10.7326/0003-4819-126-6-199703150-00003. View

11.

Larsson K, Lindh E, Lind L, Persson I, Ljunghall S . Increased fracture risk in hypercalcemia. Bone mineral content measured in hyperparathyroidism. Acta Orthop Scand. 1989; 60(3):268-70. DOI: 10.3109/17453678909149275. View

12.

Brown E, Pollak M, Hebert S . The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med. 1998; 49:15-29. DOI: 10.1146/annurev.med.49.1.15. View

13.

Hamdy N, Gray R, McCloskey E, Galloway J, Rattenbury J, Brown C . Clodronate in the medical management of hyperparathyroidism. Bone. 1987; 8 Suppl 1:S69-77. View

14.

Kochersberger G, Buckley N, Leight G, Martinez S, Studenski S, Vogler J . What is the clinical significance of bone loss in primary hyperparathyroidism?. Arch Intern Med. 1987; 147(11):1951-3. View

15.

Shane E, Baquiran D, Bilezikian J . Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med. 1981; 95(1):23-7. DOI: 10.7326/0003-4819-95-1-23. View

16.

Chandrasekharappa S, Guru S, Manickam P, Olufemi S, Collins F, Emmert-Buck M . Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997; 276(5311):404-7. DOI: 10.1126/science.276.5311.404. View

17.

Grey A, Stapleton J, Evans M, Tatnell M, Reid I . Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med. 1996; 125(5):360-8. DOI: 10.7326/0003-4819-125-5-199609010-00002. View

18.

Ledger G, Khosla S, Lindor N, Thibodeau S, Gharib H . Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. Ann Intern Med. 1995; 122(2):118-24. DOI: 10.7326/0003-4819-122-2-199501150-00008. View

19.

Marcus R, Madvig P, CRIM M, Pont A, Kosek J . Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med. 1984; 100(5):633-40. DOI: 10.7326/0003-4819-100-5-633. View

20.

Khan A . Primary hyperparathyroidism: diagnosis and management. Endocr Pract. 1997; 3(1):22-6. DOI: 10.4158/EP.3.1.22. View